Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Accuray and RaySearch Announce Long-Term Collaboration Agreement Regarding the RayCare® Oncology Information System

SUNNYVALE, Calif., and STOCKHOLM, Sweden July 13, 2015 -- Accuray Incorporated (Nasdaq: ARAY) and RaySearch Laboratories AB (publ) (NASDAQ OMX Stockholm: RAY B) announced today they have signed a long-term collaboration agreement which will allow Accuray to co-market and offer the RayCare®oncology information system (OIS) which is currently in development at RaySearch. Under the contract, Accuray will have the opportunity to offer RayCare®in several designated major radiation therapy markets, making available a fully-integrated solution with the TomoTherapy®and CyberKnife®System product

Read original

ArcelorMittal, LanzaTech and Primetals Technologies announce partnership to construct breakthrough €87m biofuel production facility

13 July 2015 - ArcelorMittal, the world’s leading steel and mining company, LanzaTech, the carbon recycling company, and Primetals Technologies, a leading technology and service provider to the iron and steel industry today announce they have entered into a letter of intent to construct Europe’s first-ever commercial scale production facility to create bioethanol from waste gases produced during the steelmaking process. The resulting bioethanol can cut greenhouse gas emissions by over 80 per cent compared with conventional fossil fuels. It will predominantly be used in gasoline blending, but

Ragdale Hall – the perfect end of term pampering for teachers…

It’s that time of year when pupils and teachers across the UK will be eagerly anticipating that liberating feeling that washes over them at the sound of the last class bell!If the last few weeks are starting to drag, planning something to look forward to may help.  It will also fill some of the blissful empty July and August spaces on the calendar!   What better place to visit than Ragdale Hall in Leicestershire?  It promises to offer a peaceful and calming environment, a far cry from a classroom full of fidgety five year olds or exam weary teens. Many teachers will be in

SimCorp A/S – Share buyback program

On 17 February 2015 SimCorp A/S announced a share buyback program in compliance with the provisions of Commission Regulation No. 2273/2003 of 22 December 2003, also referred to as the “Safe Harbour”. In connection with the program SimCorp A/S will repurchase shares for an amount of up to EUR 10.0m (approx. DKK 74.4m) in the period from 23 February to 14 August 2015. The following transactions have been executed under the program:   Date                  Number Average purchase Amount (DKK)  of price (DKK per

Notice of Extraordinary General Meeting in SWECO AB (publ)

Sweco AB convenes an Extraordinary General Meeting in SWECO AB (publ) to be held on Monday 24 August 2015 at 3 p.m. CET at Sweco's head office, Gjörwellsgatan 22, StockholmNotification Holders of shares registered in their own name in the share register maintained by Euroclear Sweden AB by Tuesday, 18 August 2015, and who have notified the company of their intention to participate by Tuesday, 18 August 2015 at the following address: Sweco AB, “Sweco Extraordinary General Meeting 2015”, Box 7835, 103 98 Stockholm, are entitled to participate in the meeting. Notification of intention to

Read original

The Danish ministry of health and Formpipe signs new contract worth SEK 1.5 million

The Danish ministry of health and Formpipe signs a contract for the Grant Management product TAS. The total order value amounts to SEK 1.5 million for a duration of four years. The Danish ministry of health choose TAS as their new Grants Management solution, the focus has been on compliance, automation and risk management. The ministry wanted the best standard solution on the market to ensure best practice processes and more flexibility than in their existing Grants Management solution. “We are very pleased that the Danish Ministry of Health has selected to cooperate with us and we

Kværner ASA: Invitation to presentation of 2nd quarter results 2015

13 July 2015 - Kværner ASA will publish its 2nd quarter results 2015 at the Oslo Stock Exchange on Thursday 16 July 2015 at 07:00 CET. The results presentation will be held at Kvaerner's new offices at Fornebuporten, Oksenøyveien 10 at 08:00 CET the same morning. We invite investors, analysts and the media to Kvaerner's results presentation: Date: Thursday 16 July 2015Time: 08:00 CETLocation: Fornebuporten, Oksenøyveien 10, 1366 LysakerLanguage: English To attend the presentation, please register by emailing ir@kvaerner.com.The presentation will be broadcast live on www.

Telephone conference in connection with Interim report

Collector AB (publ) will publish its report for the first six months of 2015 on Friday 17 July around 08.15 CET. A telephone conference with the opportunity to pose questions will be held at 09.30 am on the same day, with CEO Stefan Alexandersson, and CFO Pia-Lena Olofsson  presenting the report.The telephone conference will be held in Swedish and streamed live on www.financialhearings.com. To join the telephone conference, please call: +46 8 566 426 96. The switchboard will open at 9.25 CET.  A recording of the telephone conference, including the presentation materials, will be made

Recipharm secures additional bank financing for continued growth

Recipharm has  entered a new five-year SEK 1 500 million term loan facility with three of the largest banks in Scandinavia, DNB, Handelsbanken  and Swedbank in addition to the revolving credit facility of SEK 1 500 million arranged in September 2014. The total bank loan facilities from this group of banks then amounts to SEK 3 000 million.The term loan facility of SEK 1 500 million will serve as an additional resource to facilitate future expansion plans set in place for the business. At the end of the first quarter 2015 Recipharm Group had cash of SEK 607 million and interest bearing

NOTE’s Interim Report January–June 2015

Financial performance April–June• Sales were SEK 279.5 (247.6) million.• Operating profit was SEK 11.2 (7.5) million.• Operating margin was 4.0% (3.0%).• Profit after financial items was 9.2 (7.1) million.• Profit after tax was SEK 8.5 (5.7) million, corresponding to SEK 0.29 (0.20) per share.• Cash flow after investments was SEK -18.0 (-8.2) million, or SEK -0.62 (-0.28) per share.Financial performance January–June• Sales were SEK 554.8 (480.4) million.• Operating profit was 23.1 (13.3) million.• Operating margin was 4.2% (2.8%).• Profit after financial items was 20.2

Interim Report January - June 2015

SUMMARY FOR JANUARY - JUNE 2015 · Net sales SEK 296,1 M (217,6) · Profit before tax SEK 43,8 M (24,3) · Operating margin 16 % (12) · Earnings per share before dilution SEK 5,77 (3,43) · Cash flow from operations SEK 99,4 M (90,5) SUMMARY FOR APRIL - JUNE 2015 · Net sales SEK 152,7 M (116,7) · Profit before tax SEK 22,2 M (12,4) · Operating margin 15 % (11) · Earnings per share before dilution SEK 2,83 (1,85) · Cash flow from operations SEK 25,8 M (26,2) · Revolving credit facility of SEK 250 M for acquisitions CEO´S COMMENTSOn 30 June, Vitec

Aerocrine is delisted today

As previously announced, today is the last day of trading in the Aerocrine stock on Nasdaq Stockholm. Following completion of the recent public tender offer, Circassia Pharmaceuticals Plc ("Circassia") has initiated a mandatory redemption procedure to acquire all shares not already held by Circassia. Further information on the redemption procedure will be sent to remaining shareholders within short.For more information, please contact: Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336 About Aerocrine Aerocrine AB is a medical products company focused on the

Regulatory Announcement – Director Declaration

13 July 2015 Genel Energy plc Regulatory Announcement - Director Declaration Further to the announcement made earlier today, the Company confirms that, save as set out below there are no disclosures to be made under paragraph 9.6.13 of the Listing Rules in relation to Murat Özgül. In 2010 the Financial Services Authority ("FSA") imposed a financial penalty on Murat Özgül in respect of share dealing around the time of a possible merger of Genel Enerji and Heritage Oil. The FSA, in their public statement, acknowledged that Murat Özgül did not set out to commit market abuse. -

D. Carnegie & Co’s divestment of Gothenburg-portfolio postponed

The previously announced sale of D. Carnegie & Co’s - listed on Nasdaq Stockholm - Gothenburg-portfolio has been cancelled as the buyer failed to secure financing. Since Gothenburg is not within D. Carnegie & Co’s prioritized investment scope, a search for another buyer will be initiated during the fall.For further information, please contact:Ulf Nilsson, CEO, D. Carnegie & Co, tel. +46 (0)8 – 121 317 25. D. Carnegie & Co AB (publ) is required to make this information public under the provisions of the Swedish Financial Markets Act and/or the Swedish Financial Instruments Trading Act.

Directorate Change

13 July 2015 Genel Energy plc Directorate Change Genel Energy plc ("Genel" or "the Company") announces that, as of 12 July 2015, Rodney Chase has resigned from the Company. Tony Hayward has been appointed Chairman in his stead. Murat Özgül, previously President, Turkey and KRI, has become Chief Executive, and been appointed to the board. In his role as Chairman, Tony will oversee the strategy of the Company and the effective running of the board, with Murat focusing on the day-to-day management of Genel, including operational performance and the delivery of Genel's growth

Trading and operations update

13 July 2015 Genel Energy plc Trading and operations update Genel Energy plc ("Genel" or "the Company") issues the following trading and operations update in advance of the Company's half-year 2015 results, which are scheduled for release on 6 August 2015. The information contained herein has not been audited and may be subject to further review. Tony Hayward, Chairman of Genel, said: "Production has grown rapidly in the first half of the year, increasing 41% year on year, with operational delivery driving record volumes above 100,000 bopd net to Genel on peak days. This

Handelsbanken’s interim report for January-June 2015 will be presented on July 21

Handelsbanken will present its results for January­‑June 2015 in Stockholm on July 21, 2015 at 9:00 a.m. CET at a meeting with the media and analysts. The interim report for January‑June 2015 will be published at 7:00 a.m. CET on July 21, 2015. A telephone conference will be held at 11:00 a.m. CET (5:00 a.m. EST), whereUlf Riese, CFO, will present the figures and give his comments. There will also betime for questions from the participants. UK number: +44 (0)203 364 5374Swedish number: +46 (0)8 505 564 74US number: +1 855 753 2230 Instructions 1. Dial +xx xxx xx 10

Sweco launches recommended public offer for Grontmij as planned

Sweco launches recommended public offer for Grontmij as planned and publishes Offer Memorandum, Prospectus and EGM convening notice.On 1 June 2015, Sweco AB (publ) (“Sweco”) and Grontmij N.V. (“Grontmij”) jointly announced (the "Initial Announcement") the intended recommended public offer by Sweco for all issued and outstanding ordinary shares in the capital of Grontmij for an offer price of EUR 1.84 in cash (cum dividend) and 0.22195 Sweco B share for each Grontmij ordinary share, subject to customary conditions (the "Offer"). On 26 June 2015, Sweco and Grontmij confirmed that they are

Read original

Leading European health centers to improve cranial radiosurgery with Elekta’s new Leksell Gamma Knife Icon

STOCKHOLM, July 13 – Three foremost medical centers in the United Kingdom and Germany have ordered and are now planning upgrades to Elekta’s latest generation stereotactic radiosurgery system for the brain, Leksell Gamma Knife® Icon™ , to provide the most advanced brain radiosurgery treatments for their patients. The centers are University Medical Centre Mannheim (UMC, Mannheim, Germany), Bristol Gamma Knife Centre, University Hospitals Bristol NHS Foundation Trust (Bristol, UK) and The Leeds Gamma Knife Centre at St James’s Institute of Oncology (Leeds, UK).

Casumo launches outstanding new mobile casino

After months of development, Casumo's new mobile casino is about to be released. New Casinos  has received a sneak preview and are first to report about the new outstanding mobile platform from Casumo. See screenshots and get inside information about how it works on the iPhone 6 Plus.Casumo  has long been working to create an innovative mobile casino, compatible as many tablets and mobile devices as possible. The goal has been to create an industry leading mobile casino easy to understand, maximising the limited screen

Pair of hard-fought seventh place results hoist Malja into series top 10

Swedish driver closes to within five points of team-mate Tio Ellinas on mixed weekend for Strakka Racing at Red Bull RingFormula Renault 3.5 Series front-runners Gustav Malja and Tio Ellinas battled the odds impressively during the fifth event of the 2015 season on Sunday, 12th July, to earn some well-deserved points finishes from lower than expected qualifying positions. Ellinas dominated the early part of the weekend at the Red Bull Ring with the fastest time in pre-event testing, and he went on to also deliver top two pace in final practice on Saturday, 11th July. With qualifying

Global psoriasis survey calls attention to unmet needs in education of patients, physicians and policy makers

International Federation of Psoriasis Associations announces final results from global psoriasis survey at 4th World Psoriasis & Psoriatic Arthritis Conference(Stockholm, July 11, 2015)Today, at the 4th World Psoriasis & Psoriatic Arthritis Conference, the International Federation of Psoriasis Associations, IFPA, presents the results of a global survey to identify strategic activities to cope with unmet needs of patients with psoriasis. The online survey, which launched in June of 2014 and closed at end of May 2015, was developed by IFPA to gain insights on which activities, or “tools”,

FDA approves Rexulti (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia

· There are approximately 15 million adults in the US with major depressive disorder (MDD), and many of them have an inadequate response to monotherapy with antidepressants[i] [,] [ii] . There are 2.4 million adults with schizophrenia in the US, many of whom continue to need effective treatments[i] · The US approval of Rexulti is based on a clinical program in which Rexulti showed improvement vs. placebo in symptoms when used as an adjunctive

There are no items matching the current filter
There are no more items matching the current filter
Back to top